Sep 21, 2020
Striving for Consensus on the Optimal Management of Metastatic
Non-Small Cell Lung Cancer — Faculty Presentation 3: Second- and
later-line treatment for patients with metastatic NSCLC without a
targetable tumor mutation who have experienced disease progression
on a checkpoint inhibitor alone or combined with chemotherapy — Dr
Garon.
CME information and select publications